Short Interest in Kamada Ltd. (NASDAQ:KMDA) Increases By 57.0%

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) was the recipient of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 48,500 shares, an increase of 57.0% from the May 15th total of 30,900 shares. Currently, 0.2% of the company's shares are sold short. Based on an average daily volume of 95,400 shares, the days-to-cover ratio is presently 0.5 days.

Institutional Trading of Kamada

A number of institutional investors and hedge funds have recently modified their holdings of KMDA. Huntleigh Advisors Inc. purchased a new position in shares of Kamada during the first quarter valued at approximately $863,000. Jane Street Group LLC bought a new stake in Kamada in the 1st quarter worth approximately $582,000. Goldman Sachs Group Inc. purchased a new stake in Kamada during the 1st quarter valued at $497,000. Aristides Capital LLC raised its stake in Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock valued at $387,000 after buying an additional 6,850 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in shares of Kamada by 119.9% during the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company's stock valued at $341,000 after buying an additional 28,165 shares during the period. Institutional investors own 20.38% of the company's stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $11.00 target price on shares of Kamada in a research note on Thursday, March 6th. Sidoti raised shares of Kamada to a "hold" rating in a research report on Thursday, May 8th. Benchmark reiterated a "buy" rating and set a $15.00 price target on shares of Kamada in a research report on Thursday, May 15th. Finally, Wall Street Zen raised shares of Kamada from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, May 21st. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $14.67.

Kamada Stock Up 1.1%

Shares of NASDAQ KMDA traded up $0.08 during trading on Wednesday, reaching $7.22. The company had a trading volume of 60,954 shares, compared to its average volume of 93,939. Kamada has a 12-month low of $4.74 and a 12-month high of $9.16. The business's 50-day moving average is $6.70 and its 200 day moving average is $6.74. The stock has a market cap of $415.22 million, a PE ratio of 24.90, a P/E/G ratio of 0.95 and a beta of 0.94.

Kamada (NASDAQ:KMDA - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, meeting analysts' consensus estimates of $0.07. Kamada had a net margin of 9.60% and a return on equity of 6.31%. The business had revenue of $44.02 million during the quarter, compared to analyst estimates of $154.06 million. On average, analysts anticipate that Kamada will post 0.23 earnings per share for the current year.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.